Research Overview

CJC-1295 (No DAC), also known as Modified GRF (1-29), is a synthetic analogue of growth hormone-releasing hormone studied in metabolic and endocrine research. It is investigated for its agonist activity at the GHRH receptor and its influence on the amplitude and frequency of pituitary growth-hormone pulses. Without the Drug Affinity Complex (DAC) it has a short circulating half-life, which makes it a common tool for studying pulsatile GH-release patterns in controlled experimental settings. No therapeutic or clinical claims are made or implied.

Primary Research Areas

• GHRH receptor agonism: investigation of GHRH receptor activation and downstream signaling in cellular and endocrine research models.
• Pulsatile growth-hormone release: experimental studies examining the amplitude and frequency of pituitary GH pulses.
• Pituitary function models: preclinical models assessing somatotropic pituitary activity and secretagogue responses.
• Secretagogue combination studies: research alongside growth-hormone secretagogues to evaluate combined effects on GH-release dynamics.

Reconstitution

For dissolving lyophilized peptide powder, laboratory practice uses a sterile research solvent such as bacteriostatic water (BAC), which supports handling stability and reduces the risk of contamination.